Leonardi Leonardo, Benassi Maria Serena, Pollino Serena, Locaputo Carmen, Pazzaglia Laura
Department of Veterinary Medicine - Veterinary Pathology, Università degli Studi di Perugia, Perugia, PG, Italy.
Oncologia Sperimentale, Istituto Ortopedico Rizzoli Istituto di Ricovero e Cura a Carattere Scientifico, Bologna, Italy.
Vet Rec Open. 2020 Mar 8;7(1):e000379. doi: 10.1136/vetreco-2019-000379. eCollection 2020.
Osteosarcoma (OS) is the most common primary malignant bone tumour in dogs and human beings, characterised by similar genetic and clinical features. With the aim to define similarities and differences in the biological aspects involved in OS progression, a comparative study was performed to create a model to improve patient outcome.
First, the expression of microRNAs (miRNAs) belonging to the cluster miR-106b-25 (miR-106b, miR-25 and miR-93-5p) in human and canine OS tissue was compared.
miR-25 and miR-106b presented a variable expression not significantly different from the corresponding normal bone, while miR-93-5p expression was increased in all OS specimens, with higher levels in the canine subset compared with human. Accordingly, its target p21 presented a weaker and less homogeneous immunostaining distribution in the canine group. Given the high expression of miR-93-5p in all OS specimens, the functional response of human 143B and canine DAN OS cells to miRNA inhibition was evaluated. Although p21 expression increased after miR-93-5p inhibition both at mRNA and protein level, a more significant cell response in terms of proliferation and apoptosis was seen in canine OS cells.
In conclusion, canine OS tissue and cell line presented higher expression levels of miR-93-5p than human OS. In addition, the introduction of miR-93-5p inhibitor caused a cell response in 143B and DAN that differed for the more intense functional impact in the canine OS cell line.
骨肉瘤(OS)是犬类和人类中最常见的原发性恶性骨肿瘤,具有相似的遗传和临床特征。为了确定骨肉瘤进展过程中生物学方面的异同,进行了一项比较研究以建立一个改善患者预后的模型。
首先,比较了人类和犬类骨肉瘤组织中属于miR-106b-25簇(miR-106b、miR-25和miR-93-5p)的微小RNA(miRNA)的表达。
miR-25和miR-106b的表达存在差异,但与相应的正常骨组织相比无显著差异,而miR-93-5p在所有骨肉瘤标本中的表达均升高,犬类样本中的水平高于人类。相应地,其靶标p21在犬类组中的免疫染色分布较弱且不均匀。鉴于miR-93-5p在所有骨肉瘤标本中高表达,评估了人类143B和犬类DAN骨肉瘤细胞对miRNA抑制的功能反应。尽管miR-93-5p抑制后p21在mRNA和蛋白质水平均升高,但在犬类骨肉瘤细胞中观察到更显著的增殖和凋亡细胞反应。
总之,犬类骨肉瘤组织和细胞系中miR-93-5p的表达水平高于人类骨肉瘤。此外,引入miR-93-5p抑制剂导致143B和DAN细胞产生反应,且犬类骨肉瘤细胞系中的功能影响更强烈,两者存在差异。